Ezetimibe lipid lowering trial on cholesterol absorption-synthesis and prevention of atherrosclerosis in 75 or older with hight risk hyper LDL cholesterolemia
Not Applicable
- Conditions
- Hyper-LDL-cholesterolemia
- Registration Number
- JPRN-UMIN000017769
- Lead Sponsor
- International University of Health and Welfare
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 1300
Inclusion Criteria
Not provided
Exclusion Criteria
(1)Serum TG level400 mg/dL (2) History of myocardial infarction (3) History of PCI or CABG (4) Angina pectoris requiring treatment (5) Recent history of stroke(within 6 months) (6) 1. AST100 IU/L 2. ALT100 IU/L 3. liver chirosis (7) Serum creatinine level3.0 mg/dL (8) Cancer (9) Dementia (10) Familial hyperchoresterolemia (11) Atrial fibrillation (12) Allergy to ezetimibe (13) Patients participating in other clinical trials (14) Patients inappropriate for the trial judged by investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 0 to 24weeks (1)changes in cholesterol absorption and synthesis (2)changes in inflammation markers (3)changes in lipoproteins(RLPcholesterol, small dense LDL etc), oxydised phospholipid, oxdised cholesterol) (4)NT-proBNP
- Secondary Outcome Measures
Name Time Method relation to composite cardiovascular events(same as EWTOPIA75)